Company logo

DARE - Daré Bioscience, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Diego, United States
Type: Equity

DARE price evolution
DARE
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $15.66 $13.33 $19.83 $34.67
Short term investments
Net receivables $1.13 $0.57 $2.4 $1.7
Inventory
Total current assets $22.44 $22.24 $29.51 $43.04
Long term investments
Property, plant & equipment $0.06 $0.05 $0.06 $0.52
Goodwill & intangible assets
Total noncurrent assets $2.62 $0.97 $0.85 $0.79
Total investments
Total assets $25.05 $23.21 $30.37 $43.83
Current liabilities
Accounts payable $4.99 $6.54 $2.7 $2.03
Deferred revenue $1.21 $1.21 $1 $1
Short long term debt $0.19 $0.27 $0.34 $0.4
Total current liabilities $26.34 $24.7 $24.34 $31.62
Long term debt $0.02 $0.06 $0.09
Total noncurrent liabilities $1 $1.23 $1.06 $1.09
Total debt $0.19 $0.3 $0.39 $0.49
Total liabilities $27.34 $25.93 $25.4 $32.71
Shareholders' equity
Retained earnings -$166.18 -$157.88 -$149.12 -$141.07
Other shareholder equity -$0.42 -$0.4 -$0.37 -$0.35
Total shareholder equity -$2.29 -$2.72 $4.97 $11.11
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $34.67 $51.67 $4.67 $4.78
Short term investments
Net receivables $1.7 $1.15 $0.46 $0.56
Inventory
Total current assets $43.04 $55.3 $6.98 $6.44
Long term investments
Property, plant & equipment $0.52 $0.03 $0.04 $0.06
Goodwill & intangible assets
Total noncurrent assets $0.79 $0.51 $0.57 $1
Total investments
Total assets $43.83 $55.81 $7.55 $7.44
Current liabilities
Accounts payable $2.03 $2.1 $1.02 $1.08
Deferred revenue $1 $1 $1
Short long term debt $0.4 $0.27 $0.71 $0.41
Total current liabilities $31.62 $16.05 $7.66 $5.61
Long term debt $0.09 $0.04 $0.39
Total noncurrent liabilities $1.09 $1 $1.04 $1.39
Total debt $0.49 $0.27 $0.76 $0.8
Total liabilities $32.71 $17.05 $8.7 $7
Shareholders' equity
Retained earnings -$141.07 -$110.13 -$71.43 -$44.02
Other shareholder equity -$0.35 -$0.15 -$0.09 -$0.1
Total shareholder equity $11.11 $38.75 -$1.15 $0.44
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $1
Cost of revenue
Gross Profit $1
Operating activities
Research & development $6.67 $6.04 $5.02 $12.98
Selling, general & administrative $2.7 $2.92 $3.34 $3.23
Total operating expenses $9.4 $8.99 $8.38 $16.23
Operating income -$8.4 -$8.99 -$8.38 -$16.23
Income from continuing operations
EBIT -$8.3 -$8.76 -$8.04 -$15.94
Income tax expense
Interest expense
Net income
Net income -$8.3 -$8.76 -$8.04 -$15.94
Income (for common shares) -$8.3 -$8.76 -$8.04 -$15.94
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $10
Cost of revenue
Gross Profit $10
Operating activities
Research & development $30.04 $30.62 $20.77 $8.55
Selling, general & administrative $11.24 $8.35 $6.55 $5.27
Total operating expenses $41.39 $39.07 $27.4 $14.34
Operating income -$31.39 -$39.07 -$27.4 -$14.34
Income from continuing operations
EBIT -$30.95 -$38.7 -$27.4 -$14.26
Income tax expense
Interest expense
Net income
Net income -$30.95 -$38.7 -$27.4 -$14.26
Income (for common shares) -$30.95 -$38.7 -$27.41 -$15.05
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$8.3 -$8.76 -$8.04 -$15.94
Operating activities
Depreciation $0 $0 $0 $0
Business acquisitions & disposals
Stock-based compensation $0.64 $0.65 $0.62 $0.53
Total cash flows from operations -$7.97 -$6.59 -$16.12 -$5.9
Investing activities
Capital expenditures -$0.02 -$0
Investments
Total cash flows from investing -$0.02 -$0
Financing activities
Dividends paid
Sale and purchase of stock $8.11 $0.45 $1.3 -$0
Net borrowings $0.47
Total cash flows from financing $8.58 $0.45 $1.3 -$0
Effect of exchange rate -$0.02 -$0.03 -$0.02 $0.18
Change in cash and equivalents $0.57 -$6.17 -$14.84 -$5.72
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$30.95 -$38.7 -$27.4 -$14.26
Operating activities
Depreciation $0.05 -$0.07 -$0.12 -$0.02
Business acquisitions & disposals $6.14
Stock-based compensation $2.16 $1.6 $0.74 $0.46
Total cash flows from operations -$18.09 -$28.76 -$25.23 -$13.32
Investing activities
Capital expenditures -$0.06 -$0.01 -$0.02
Investments
Total cash flows from investing -$0.06 -$0.01 -$0.02 $6.14
Financing activities
Dividends paid
Sale and purchase of stock $1.34 $75.85 $24.76 $5.15
Net borrowings $0.37
Total cash flows from financing $1.34 $75.85 $25.13 $5.15
Effect of exchange rate -$0.2 -$0.06 $0.01 -$0.01
Change in cash and equivalents -$17 $47 -$0.11 -$2.03
Fundamentals
Market cap $53.96M
Enterprise value $38.50M
Shares outstanding 98.29M
Revenue $1000.00K
EBITDA -$41.03M
EBIT -$41.05M
Net Income -$41.05M
Revenue Q/Q InfinityT%
Revenue Y/Y -90.00%
P/E ratio -1.31
EV/Sales 38.50
EV/EBITDA -0.94
EV/EBIT -0.94
P/S ratio 53.96
P/B ratio -28.87
Book/Share -0.02
Cash/Share 0.16
EPS -$0.42
ROA -134.08%
ROE -1.48K%
Debt/Equity 2.94
Net debt/EBITDA -0.28
Current ratio 0.85
Quick ratio 0.85